Amarin’s Fat-lowering Drug Meets Goals In First Of Two Late-stage Trials
Amarin’s Fat-lowering Drug Meets Goals In First Of Two Late-stage Trials
Monday before the bell, Amarin Corp. plc (AMRN) announced that its first late-stage clinical trial of lead drug candidate – the fat-lowering AMR101, met the primary endpoints with highly statistically significant reductions in triglycerides.
Read more on RTT News
Amarin’s Fat-lowering Drug Meets Goals In First Of Two Late-stage Trials
Monday before the bell, Amarin Corp. plc (AMRN) announced that its first late-stage clinical trial of lead drug candidate – the fat-lowering AMR101, met the primary endpoints with highly statistically significant reductions in triglycerides.
Read more on RTT News
GlaxoSmithKline to increase shareholding in Theravance as pair develop lung drug
LONDON – British drug maker GlaxoSmithKline PLC says it plans to increase its shareholding in U.S. biotech company Theravance Inc. London-based Glaxo said Monday that the two companies have agreed for Glaxo to purchase 5.75 million shares of Theravance common stock at a price of US$ 22.50 per share.
Read more on Brandon Sun